Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy.

PURPOSE

To examine changes in intraocular pressure (IOP) in patients with thyroid eye disease (TED) following teprotumumab.

MATERIALS AND METHODS

A retrospective review of 17 patients with TED who received teprotumumab between January 2020 and September 2021 was conducted. IOP, extent of proptosis, and clinical activity score were reviewed at baseline and at 6 weeks, 12 weeks, and 24 weeks for patients undergoing teprotumumab treatment. The primary outcome measure was change in IOP, while secondary outcome measures included changes in proptosis and clinical activity score.

RESULTS

Of the 17 patients (34 eyes) with TED who were treated with teprotumumab, the mean age was 50.5 years, and 15 (88%) were female. The mean baseline IOP was 20 mm Hg (range 13-28), and the mean baseline clinical activity score was 3.8 (range 0-6). Of the 34 eyes examined at baseline, examinations were repeated in 16 at 6 weeks, 26 at 12 weeks, and 8 at 24 weeks. At week 6 of treatment, mean IOP decreased by 4.9 mm Hg ( < 0.0001). At week 12 of treatment, mean IOP decreased by 4.6 mm Hg ( < 0.0001). Mean IOP was decreased at last record of follow-up by 4.9 mm Hg ( < 0.0001).

CONCLUSION

Among patients with TED, teprotumumab treatment was associated with a reduction in IOP.